Show Summary Details
Page of

The treatment of cyclothymia 

The treatment of cyclothymia
The treatment of cyclothymia

Giulio Perugi

, Giulia Vannucchi

, and Lorenzo Mazzarini

Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2021. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 26 January 2022

The treatment of cyclothymia is problematic due to its rather complex clinical picture (early onset, lack of clear-cut episodes, high co-morbidity), a challenging patient–doctor relationship and a high sensitivity to medications. This chapter summarizes available evidence on pharmacological treatment, psychoeducation, and psychotherapy for cyclothymic patients. The management of cyclothymia should rely on integrated strategies. The psychopharmacological treatment has to follow the principle of ‘go slow and stay low’. Mood stabilizers should be the first option and antidepressants and antipsychotics should be used cautiously and for short periods of time to manage depressive, anxious, or hypomanic symptoms. Psychoeducation should be started from the beginning and is aimed to promote a better knowledge of the disorder and its effects on daily life as well as adherence to medications. The inclusion of individual psychotherapeutic treatments (eg, cognitive behavioural treatment) should also be considered.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.